Social Performance

Also known as: TP-7, Selank Spray

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally cleaved from the Fc region of immunoglobulin G. The original tuftsin molecule has well-documented immunomodulatory and neurotropic effects but is rapidly degraded by peptidases in plasma, limiting its therapeutic utility. Selank adds a Pro-Gly-Pro tail to the tuftsin sequence, which confers resistance to enzymatic degradation while preserving pharmacological activity. In Russia, Selank has been approved since 2004 for the treatment of generalized anxiety disorder (GAD) and is available by prescription at pharmacies across the Russian Federation and several neighboring countries. It is marketed as a 0.15% intranasal solution under the brand name "Selank" (╨í╨╡╨╗╨░╨╜╨║) by Peptogen, a Moscow-based pharmaceutical company. In Western markets, Selank has never been submitted for FDA, EMA, or other major regulatory approval — not because of unfavorable data, but because the commercial pharmaceutical industry has no mechanism to profit from a peptide with an expired patent and no Western development sponsor. As a result, Selank circulates in the biohacking and peptide-curious community primarily as a "research chemical" through specialty peptide suppliers, where it is sold in intranasal spray or injectable formulations. The pharmacological profile of Selank is distinctive among anxiolytics. Unlike benzodiazepines, it does NOT cause sedation, cognitive dulling, tolerance, dependence, or withdrawal. Unlike SSRIs, it has rapid onset (within 30-60 minutes of intranasal administration) and effects that outlast plasma presence. Unlike buspirone, it does not require weeks of chronic dosing to manifest effects. The compound appears to work through modulation of multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and endogenous opioid — producing what the Russian clinical literature describes as an "anxiolytic + nootropic" profile: the user feels calmer but also more mentally engaged, not sedated. This unusual combination has driven substantial interest in Western biohacking circles as an alternative or adjunct to conventional anxiety pharmacology. Selank has been studied in Russian clinical populations for over two decades with a consistent efficacy and safety pattern across roughly 30-50 published clinical papers. The evidence base is real but has important limitations: most trials are Russian-language, published in Russian journals, with small sample sizes (often 30-100 patients), and use Russian psychiatric rating scales rather than the validated Western instruments (GAD-7, HAM-A, Beck Anxiety Inventory) that would facilitate cross-validation. Western meta-analyses and systematic reviews are essentially nonexistent. The Russian regulatory approval is real and meaningful — Russian drug regulation, while different from FDA standards, does require efficacy and safety evidence — but it does not automatically translate to confidence in Western evidence-based medicine frameworks. For the biohacking community, Selank's appeal is the combination of (1) rapid-acting anxiolysis without sedation, (2) cognitive enhancement rather than dulling, (3) favorable safety profile across decades of Russian use, (4) non-addictive, non-dependence-producing pharmacology, and (5) intranasal delivery that is simple and needle-free. Its limitations are (1) thin Western evidence base, (2) variable quality from research chemical suppliers, (3) lack of FDA regulation or oversight, (4) modest effect magnitude in some users relative to expectations, and (5) cost relative to generic anxiety pharmacology. This entry covers the pharmacology, clinical evidence, practical use considerations, and honest framing of the evidence gaps. Cross-reference with Semax, DSIP, and Epithalon for a complete picture of the Russian research peptide landscape.

Also known as: NASA-Selank, N-Acetyl Selank

Acetylated form of Selank peptide with enhanced bioavailability, commonly used as a nasal spray for anxiolytic and nootropic effects.

Also known as: OT

Oxytocin is a nine-amino-acid cyclic peptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) synthesized in magnocellular neurons of the hypothalamic paraventricular (PVN) and supraoptic nuclei (SON), then transported along axons to the posterior pituitary for release into systemic circulation. Vincent du Vigneaud synthesized oxytocin in 1953, becoming the first scientist to chemically synthesize a peptide hormone and earning the 1955 Nobel Prize in Chemistry for the achievement. The isolation and characterization of oxytocin marked the beginning of modern peptide pharmacology and established the template for all subsequent peptide drug development. Oxytocin's classical roles — uterine contraction during labor and milk ejection during breastfeeding — have been understood since the early 20th century and form the basis of its FDA approval as Pitocin (synthetic oxytocin) for labor induction and augmentation, postpartum hemorrhage control, and lactation support. The story of oxytocin as something far more interesting than a reproductive hormone began in the 1990s, when researchers including Sue Carter, Thomas Insel, and Larry Young discovered that oxytocin released centrally in the brain (rather than peripherally through the posterior pituitary into blood) acts as a profound modulator of social behavior, pair bonding, trust, empathy, maternal behavior, and sexual response. Prairie vole studies showed that central oxytocin (and its sister peptide vasopressin) mediates the difference between monogamous and promiscuous mating strategies; human studies showed that intranasally administered oxytocin modulates trust, generosity, gaze patterns, and emotional recognition (Kosfeld et al., 2005, Insel & Young, 2001). This "social neuropeptide" framing generated enormous scientific and popular interest and motivated clinical trials exploring oxytocin for autism spectrum disorders, post-traumatic stress disorder, social anxiety, schizophrenia-related social dysfunction, and relationship therapy applications. Results from those clinical trials have been more nuanced than the early excitement suggested. Large randomized controlled trials in autism have shown mixed-to-disappointing results (Sikich et al., 2021 NEJM). The initial Kosfeld "trust" finding and related social cognition effects have been difficult to replicate consistently, leading to a reckoning about methodological issues in the early oxytocin literature (Nave et al., 2015 meta-analysis). What has held up is that oxytocin does produce subtle, context-dependent effects on social and emotional processing in some people under some conditions — but it is not the universal love-and-trust drug that early popular science coverage sometimes implied. The pharmacology is more sophisticated than a simple "love hormone" narrative allows. In current clinical practice, oxytocin has well-established approval for obstetric uses (Pitocin IV for labor, Syntocinon nasal spray for milk letdown in some markets). Off-label and grey-market use of oxytocin — typically via compounded nasal spray or subcutaneous injection — is pursued for three main reasons: (1) improving sexual and emotional connection with partners, which is the most common recreational motivation and the one with the most credible (if limited) evidence base; (2) managing social anxiety, autism-spectrum social challenges, or post-traumatic stress symptoms under self-directed protocols; and (3) adjunctive use during couples therapy, psychotherapy, or other relational contexts where the modest pro-social effects may facilitate the therapeutic process. None of these off-label uses is supported by rigorous efficacy evidence comparable to what exists for approved indications, and the intranasal route that most community use relies on has significant questions about how much centrally active oxytocin actually reaches the brain after nasal administration (Leng & Ludwig, 2016). This entry covers what oxytocin does biologically, what clinical evidence exists for its various uses, and the practical realities of off-label oxytocin use including route-of-administration uncertainties, duration of effect, and limitations. Unlike many peptides covered here, oxytocin has a genuinely large scientific literature — several thousand published human studies — but separating signal from noise in that literature requires careful reading. Cross-links to related compounds include PT-141 (Bremelanotide) for central sexual arousal effects through an independent (melanocortin) mechanism, and Kisspeptin-10 for reproductive axis and desire effects through yet another distinct mechanism.

Also known as: ACTH 4-10, BDNF Spray, BDNF, Flow Spray

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, 813 Da molecular weight) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The compound is derived from ACTH(4-10) — the 4-10 amino acid fragment of adrenocorticotropic hormone — with the addition of a Pro-Gly-Pro C-terminal tail that confers resistance to enzymatic degradation while preserving neurotropic activity. Critically, Semax retains the cognitive, neurotrophic, and neuroprotective effects of its ACTH parent while completely lacking the adrenal-stimulating hormonal activity. In other words, Semax works on the brain without activating the HPA axis or affecting cortisol production — a therapeutically ideal profile. Semax was patented in 1982 by Russian researchers and achieved regulatory approval in the Russian Federation in 2000, where it is prescribed at pharmacies for cerebrovascular disorders (ischemic stroke recovery), optic nerve disorders, minimal brain dysfunction in children (ADHD-like presentations), asthenia, and various cognitive complaints. It is available in two commercial strengths: 0.1% intranasal solution for cognitive-nootropic indications and 1% intranasal solution for stroke recovery and neurological deficits. In Western markets, Semax has never been submitted for FDA, EMA, or other major regulatory approval — a pattern common to Russian neuropeptides that lack patent protection and Western pharmaceutical sponsors. It circulates in US and European biohacking communities through research chemical peptide suppliers and is considered one of the most potent, best-tolerated nootropic compounds available. The pharmacology of Semax is genuinely notable and spans multiple neurological domains. At the molecular level, Semax elevates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the brain, promotes dopaminergic and serotonergic signaling, potentiates endogenous enkephalin activity, and upregulates expression of neuroprotective genes. At the clinical level, it produces cognitive enhancement (attention, memory, executive function), mood elevation, stress tolerance, neuroprotection during ischemia, and accelerated recovery from neurological injury. Russian clinical trials in acute ischemic stroke — the best-documented Semax indication — show meaningful improvements in functional recovery when Semax is administered within 6-24 hours of stroke onset, likely through direct neuroprotection plus enhanced neurogenesis during recovery. The stroke literature is the only domain where Semax has truly rigorous clinical trial evidence (Gusev et al., 2005). In the biohacking and cognitive enhancement community, Semax has achieved a reputation as the "premier Russian nootropic" — often positioned alongside Selank, Noopept, Modafinil, and racetams in the advanced cognitive stack. Users typically report improvements in focus, working memory, verbal fluency, motivation, stress tolerance, and overall cognitive throughput. The effects are often described as "clean" — producing alertness and engagement without the jitters of stimulants, without the emotional blunting of SSRIs, and without the sedation of anxiolytics. Dose-response is relatively modest (300-900 mcg daily typical), onset is rapid (15-30 minutes after intranasal administration), and effects last several hours per dose. Chronic use over weeks produces accumulating cognitive and mood benefits that appear to outlast plasma presence. This entry covers Semax pharmacology, the genuinely rigorous Russian stroke evidence base, the more speculative cognitive enhancement applications, protocol considerations, and safety profile. It should be read as an educational reference — Semax is not FDA-approved, is distributed through gray-market channels with variable quality, and anyone considering use should obtain reliable product, start conservatively, and have realistic expectations. Cross-reference with Selank, DSIP, and Epithalon for Russian peptide context, and with Noopept, Piracetam, and Modafinil for broader nootropic comparisons.

Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. Chemically it is N-(2-adamantyl)-N-(para-bromophenyl)amine, an adamantane derivative structurally related to amantadine and memantine but pharmacologically distinct from both. What makes Bromantane unusual and clinically interesting is that it acts simultaneously as a mild dopamine reuptake inhibitor and as an activator of tyrosine hydroxylase and aromatic L-amino acid decarboxylase gene expression in mesolimbic and mesocortical dopamine neurons, producing a gentle upregulation of endogenous dopamine synthesis rather than the forceful synaptic dopamine release characteristic of amphetamines or methylphenidate; alongside this dopaminergic effect it promotes neurosteroid synthesis particularly of allopregnanolone and related GABA-A positive modulators, which is thought to underlie its anxiolytic rather than anxiogenic profile and distinguishes it from conventional stimulants that typically produce dose-dependent anxiety. The clinical positioning in Russia has been for neurasthenia, asthenic depression, chronic fatigue states, post-infectious fatigue, and adaptation support during physical and cognitive stress, with multiple placebo-controlled and active-comparator trials published in Russian and occasionally English literature reporting benefits across fatigue, attention, mood, and sleep quality scales at daily doses typically in the 50-100 mg range for 2-6 week courses. Outside Russia Bromantane has never been approved for clinical use, is not controlled under most Western drug schedules because it predates modern scheduling and does not fit amphetamine or modafinil frameworks cleanly, and circulates primarily as a research chemical or grey-market nootropic with substantial user interest in biohacker communities. Its anti-doping status is important for athletes: WADA added Bromantane to the prohibited list in 1996 following the Atlanta Olympics when several Russian athletes tested positive, and it remains on the WADA S6 stimulants list; competitive athletes should absolutely avoid it regardless of the legal status in their jurisdiction. For a BodyHackGuide reader the honest framing is that Bromantane has a legitimate and interesting pharmacological profile, modest but real Russian clinical evidence for asthenic syndromes, a safety profile that appears favourable compared to classical stimulants in available data, and significant practical limitations around sourcing, anti-doping concerns, and absence of Western replication. Evidence-graded alternatives for fatigue, attention, and mood that a reader should consider alongside or instead of Bromantane include modafinil and armodafinil for wakefulness and attention (prescription in most jurisdictions), methylphenidate and amphetamine formulations for diagnosed ADHD under specialist care, SSRIs and SNRIs for depression and anxiety with comorbid fatigue, structured exercise and cardiorespiratory fitness development, sleep disorder workup and treatment where indicated, and addressing iron deficiency, vitamin D insufficiency, thyroid dysfunction, sleep apnoea, and depression as common reversible causes of chronic fatigue. Internal cross-links include noopept, selank, semax, bpc-157, modafinil, methylene-blue, nad, and sulbutiamine where those entries exist.

Also known as: β-phenyl-γ-aminobutyric acid, beta-phenyl-GABA, Noofen, Anvifen, Fenibut, Фенибут, phenigamma, phenybut

Phenibut is the common Western name for β-phenyl-γ-aminobutyric acid (beta-phenyl-GABA; Russian trade names Phenibut/Фенибут, Noofen, Anvifen), a Soviet-era anxiolytic and nootropic developed in the 1960s at the Herzen State Pedagogical Institute in Leningrad under Vsevolod Vasilievich Perekalin. Structurally, it is the GABA molecule with a phenyl ring attached to the β-carbon — a modification that dramatically increases lipophilicity and allows the compound to cross the blood-brain barrier (unlike GABA itself, which does not meaningfully penetrate the CNS after oral dosing). In the Soviet Union and, later, the Russian Federation and several CIS states, phenibut is a prescription medication approved for asthenia, generalised anxiety, pre-operative anxiety, insomnia related to anxiety, post-traumatic stress reactions, vestibular disorders, motion sickness, stuttering, and several pediatric indications. It was reportedly included in the Soviet cosmonaut medical kit in the 1970s — a detail endlessly repeated in online marketing that is often used to imply safety and efficacy, though the actual context (managing acute stress in a highly selected, closely monitored population) is quite different from the way most contemporary users take it. Outside of Russia and the CIS, phenibut has no regulatory approval. It is not a recognised medicine in the United States, the United Kingdom, the European Union, Canada, or Australia, and it is not listed on any Western pharmacopoeia. Its legal status is fragmented: Australia classifies it as a Schedule 9 prohibited substance; Hungary and several European countries treat it as a controlled substance; Lithuania, Latvia, Finland, and Italy have placed it under medicines regulation; the United Kingdom controls it under the Psychoactive Substances Act 2016. In the United States, phenibut is unscheduled at the federal level but the FDA has formally warned that it does not meet the statutory definition of a dietary supplement under DSHEA, issuing warning letters to multiple vendors in 2019 and 2020 for marketing phenibut-containing products. Despite this, it has been sold online as a nootropic powder or capsule under names like "Phenibut HCl" or "Phenibut FAA" (free amino acid form) for over a decade, often at doses and in contexts that Russian prescribers would consider grossly inappropriate. The core pharmacology of phenibut is that it is a GABA-B receptor agonist — in the same receptor family as baclofen and the recreational drug gamma-hydroxybutyrate (GHB) — with weaker activity at GABA-A receptors and some binding to voltage-gated α2δ calcium channels similar to pregabalin and gabapentin. This combination produces anxiolysis, mild sedation, euphoria at higher doses, and — critically — the capacity to produce severe physical dependence and withdrawal after repeated use. Phenibut's withdrawal syndrome closely resembles combined benzodiazepine and alcohol withdrawal, with insomnia, severe rebound anxiety, tremor, perceptual disturbances, and in case reports, seizures and delirium. The withdrawal risk is the single most important thing any prospective user needs to understand, and it is the primary reason phenibut appears on harm-reduction lists and clinician warning pages. The Western nootropic community's relationship with phenibut has shifted over the past decade. Early online discussion (roughly 2010-2016) treated it as a relatively benign "smart drug" or occasional anxiolytic, often with inadequate attention to tolerance and withdrawal. Over time — as case reports of severe withdrawal accumulated on PubMed (PMID 28498611, PMID 31524352, PMID 29870003, PMID 30339766, among others) and as poison control centres in Australia, Finland, and the United States began reporting regular phenibut-related calls — the community has become substantially more cautious. Responsible nootropic resources now categorise phenibut as a compound with legitimate short-term use cases (occasional social anxiety, jet-lag-related anxiety, pre-exam stress) but a narrow therapeutic window and a steep risk curve that escalates rapidly with frequency of use. Anyone considering phenibut needs to read the contraindications and protocol sections below before the description. For a more rigorously evidence-based approach to anxiety, Western first-line treatments include SSRIs (sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), and cognitive-behavioural therapy, all with substantially more strong trial data than phenibut. For acute situational anxiety in settings where a prescription is available, a single dose of propranolol or a short-acting benzodiazepine under medical supervision carries its own risks but is a better-characterised option. For a stimulant-free anxiolytic with a much lower dependence profile, see l-theanine — it lacks phenibut's potency but does not produce meaningful tolerance or withdrawal. For Russian-origin nootropics with similar geographic provenance but a very different safety profile, see selank and semax, which are peptides without the dependence liability. Phenibut is not in the same safety category as any of those compounds and should not be substituted for them without understanding the differences.

Also known as: Charisma

Active compound from kava for relaxation and sleep support.

Also known as: gamma-glutamylethylamide, N-ethyl-L-glutamine, γ-L-glutamylethylamide, Suntheanine, Theanine

L-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack. Chemically L-theanine is γ-glutamylethylamide (N-ethyl-L-glutamine), a structural analog of the excitatory neurotransmitter glutamate and its inhibitory cousin GABA — close enough to both to interact with their transporters and, at high doses, their receptors, but distinct enough to produce a characteristic combination of reduced sympathetic arousal, mildly enhanced alpha-wave EEG activity, and preserved or modestly improved attention that the literature has consistently tied to its single signature phrase: "relaxed alertness." The modern L-theanine literature traces back to Japanese tea-chemistry research in the 1950s — theanine was first isolated from green tea by Sakato in 1949 — but its Western nootropic adoption is much more recent, anchored by three key human studies: Kobayashi et al. 1998 (Japanese EEG study, alpha-wave elevation at 50-200mg oral doses), Haskell et al. 2008 (Biological Psychology PMID: 18006208), which showed that 100mg L-theanine + 50mg caffeine produces faster attention-task reaction times and subjectively better mood than either compound alone, and Kimura et al. 2007 (Biological Psychology PMID: 16930802), which demonstrated that 200mg L-theanine reduces heart rate and salivary immunoglobulin A responses to an acute stress task — the cleanest human physiology demonstration of its anxiolytic effect. Supporting RCTs include Hidese et al. 2019 (Nutrients, 4-week 200mg/day for stress and sleep in healthy adults) and Lyon et al. 2011 (Alternative Medicine Review, 200mg BID improving sleep quality in boys with ADHD). Pharmacologically, L-theanine crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1), reaching brain tissue within 30-60 minutes of an oral dose. It has a plasma half-life of roughly 1-3 hours in humans, with central nervous system exposure outlasting plasma, and it acts on multiple neurotransmitter systems simultaneously (glutamate, GABA, dopamine, serotonin, catecholamines) — but at physiologic supplement doses its effects on any single system are modest. It is a weak, broadly-acting modulator rather than a strong selective agent. This is why it does NOT cause sedation, dependence, tolerance, or rebound the way GABAergic sedatives (phenibut, benzodiazepines, Z-drugs) do — you can take 200mg daily for years without tolerance development. The largest user population is the caffeine-stack crowd — knowledge workers, students, coders, writers — taking 100-200mg caffeine daily for alertness and wanting to take the edge off the jitter without losing the focus boost. The canonical stack is 200mg caffeine + 200mg L-theanine taken together once in the morning. A second population uses it for acute stress (200mg, 30-60 minutes before a stressful event). A third cohort uses 400-600mg for schizophrenia-adjunctive anxiety based on the Ritsner 2011 data (PMID: 21208586). A fourth uses 200-400mg at bedtime for sleep quality, though the adult sleep evidence is weaker than the ADHD-boys data from Lyon 2011. Where L-theanine does NOT work: it is not a sedative, not a cognitive enhancer in isolation (the attention benefit shows up only when paired with caffeine), not a panic-attack abortive, not an SSRI substitute for clinical depression or GAD, and not equivalent to meditation or therapy for chronic anxiety. Safety profile stands out: FDA-GRAS since 2007 as Suntheanine®, rodent LD50 >5 g/kg (effectively unreachable at oral doses), decades of dietary human exposure through green tea, no dependence or withdrawal reported in any RCT. Side effects (mild headache, GI upset, dizziness at high doses) occur at placebo-comparable rates. The only meaningful practical cautions are possible additive hypotensive effect with blood-pressure medications and theoretical interaction with stimulant medications (though theanine + stimulant combinations are actually commonly used and well-tolerated). L-theanine pairs well with nearly everything. The caffeine pair is canonical. Ashwagandha is increasingly common for daytime anxiolysis. Magnesium glycinate or L-threonate pairs for evening use. Rhodiola rosea + L-theanine + caffeine is a strong "calm focus + adaptogen" stack. Avoid stacking with strong sedatives (benzodiazepines, high-dose kava, phenibut in naive users) — not because of a specific interaction but because the subjective synergy blunts the productive-calm signature L-theanine is typically used for. This is educational content and not medical advice; L-theanine is exceptionally safe for most healthy adults but blood-pressure medications, antipsychotics, and pregnancy/pediatric use warrant physician input before supplementation.

Also known as: Withania somnifera, Indian Ginseng, Winter Cherry, KSM-66, Sensoril, Shoden

Ashwagandha (Withania somnifera, also called "Indian ginseng" and "winter cherry") is the most studied and most clinically validated herbal adaptogen in the contemporary supplement market. It is the botanical anchor of Ayurvedic medicine — the indigenous medical tradition of the Indian subcontinent — where its Sanskrit name "ashwagandha" ("smell of horse") refers to the distinctive odor of the fresh root and alludes to the traditional belief that the root confers the strength of a horse. Ashwagandha has been used medicinally for over 3,000 years in Ayurvedic practice as a rasayana (rejuvenative), traditionally prescribed for fatigue, weakness, reproductive concerns, chronic inflammation, joint pain, and general vitality. In the past 15 years, modern clinical research has confirmed and expanded many of these traditional uses, producing one of the strongest randomized controlled trial evidence bases in the entire botanical medicine space — covering stress, anxiety, sleep, testosterone, muscle strength, cognitive function, and metabolic health. The pharmacologically active constituents of ashwagandha are a family of steroidal lactones called withanolides, structurally similar to both plant and animal sterols. The most studied withanolides are withaferin A (the most pharmacologically potent, concentrated in leaves), withanolide A, withanolide D, withanolide E, withanoside IV and VI, and the sitoindosides (VII–X). Standardized ashwagandha extracts are characterized by their total withanolide content (typically 1.5–10% by weight) and by their specific withaferin A content (which varies from trace amounts in root-only extracts to 0.5–2% in leaf-containing extracts). Two branded extracts dominate the clinical literature and commercial market: KSM-66 (Ixoreal Biomed, India — root-only extract standardized to at least 5% withanolides with very low withaferin A), and Sensoril (Natreon, India — root-plus-leaf extract standardized to at least 10% withanolides with 32% higher withaferin A content). These two branded extracts have materially different pharmacologic profiles and clinical use cases: KSM-66 has been studied predominantly for stress, cognitive, reproductive, and athletic performance indications; Sensoril has been studied for sleep, anxiety, and general adaptogen applications where the faster onset attributable to withaferin A is desired. BodyHackGuide covers ashwagandha as the first-line adaptogen for the stress-sleep-recovery axis, alongside companion agents like rhodiola rosea (a stimulating adaptogen with better acute-cognitive effects), bacopa monnieri (cognitive and memory focus), l-theanine (acute relaxation without sedation), magnesium glycinate (mineral cofactor for stress and sleep), and gotu kola (circulatory and cognitive Ayurvedic companion). Within this framework, ashwagandha is the anchor for cortisol normalization, chronic stress adaptation, sleep quality improvement, and recovery from physical and mental exertion. It is particularly valuable for users managing the "wired and tired" pattern of chronic sympathetic overactivation — elevated evening cortisol, poor sleep onset or depth, morning fatigue despite adequate sleep hours, difficulty winding down after work, and the sense of running on adrenaline rather than sustained energy. The contemporary clinical evidence base for ashwagandha includes more than 30 randomized controlled trials with mostly positive findings across four main indication clusters. First, stress and anxiety: Chandrasekhar 2012 (PMID 23439798) — the classic RCT of KSM-66 300 mg BID in 64 chronically stressed adults over 60 days, showing 28% reduction in serum cortisol, 44% reduction in perceived stress scale (PSS), and significant reductions in State-Trait Anxiety Inventory and General Health Questionnaire scores. Salve 2019 (PMID 32082747), Lopresti 2019 (PMID 31517876), and multiple subsequent RCTs have replicated the cortisol-reducing and stress-relieving effects. Second, sleep: Langade 2019 (PMID 31728244) — 600 mg/day of ashwagandha root extract in 80 non-clinical insomnia subjects over 10 weeks, showing significant improvements in sleep onset latency, total sleep time, and sleep efficiency on actigraphy, with parallel improvements in anxiety. Third, testosterone and reproductive health: Ambiye 2013 (PMID 24371462) in oligospermic males showed 17% testosterone elevation and improved sperm parameters; Lopresti 2019 Am J Mens Health (PMID 30854916) in aging overweight males showed 14% testosterone elevation and DHEA-S increase over 16 weeks; Chauhan 2022 PMID 35873404 in healthy adult males showed improvements in testosterone, sperm concentration, and vitality markers. Fourth, muscle strength and athletic performance: Wankhede 2015 (PMID 26609282) in resistance-training men showed significantly greater strength gains on bench press and leg extension, greater muscle mass gains, and reduced exercise-induced muscle damage markers with KSM-66 600 mg/day over 8 weeks compared to placebo; subsequent trials have confirmed the strength and body-composition effects, with more modest signals on endurance (Choudhary 2015 PMID 26730141). Beyond these four clusters, ashwagandha has emerging or supportive evidence in: cognitive function in aging and mild cognitive impairment (Choudhary 2017, Ng 2020, several small trials showing modest improvements in memory, processing speed, and executive function); metabolic health (modest improvements in fasting glucose, HbA1c, HOMA-IR, and lipid profile in small trials); thyroid function (trials in subclinical hypothyroidism showing mild TSH reduction and T3/T4 elevation — a double-edged effect that can help or harm depending on thyroid status); immune function (increased white blood cell count and improved mucosal immunity in small trials); and bipolar disorder and schizophrenia (small adjunct RCTs showing modest signals, though these are specialist-care contexts rather than self-directed supplement use). Commercially, ashwagandha is among the fastest-growing supplement ingredients of the past decade. Branded KSM-66 and Sensoril extracts dominate the quality tier of the market, appearing in products from Thorne, Life Extension, Jarrow Formulas, NOW Foods, Pure Encapsulations, Designs for Health, Himalaya, and dozens of sports nutrition and wellness brands. Typical formulations: KSM-66 at 600 mg/day (300 mg BID or as a single evening dose), Sensoril at 125–250 mg/day (usually single daily dose), or generic standardized ashwagandha at 300–600 mg/day of a 5% withanolide extract. Quality varies substantially: non-standardized "ashwagandha root powder" bulk capsules bear little resemblance to the clinical-trial standardized extracts and should generally be avoided for therapeutic intent. Cost for branded extracts: roughly $15–30 per month depending on dose and retailer. Ashwagandha is best understood as a foundational daily-use adaptogen for modern stress physiology. It is not a sedative (it does not cause drowsiness during the day), not a stimulant (it does not produce the alertness of caffeine or rhodiola), and not an acute anxiolytic (it does not produce benzodiazepine-like rapid anxiety reduction). It is, instead, a slow-acting HPA-axis modulator that reduces baseline cortisol, improves stress-response resilience, supports sleep quality, and enables recovery from sustained physical and mental exertion over weeks to months of consistent use. For BodyHackGuide users managing chronic stress, sleep disruption, recovery demands from training, or the generalized symptoms of hyper-aroused modern life, ashwagandha is the single most defensible adaptogen choice with the strongest clinical evidence base and a favorable safety profile across most populations.

Also known as: Bremelanotide

PT-141 (bremelanotide) is a cyclic 7-amino-acid synthetic melanocortin receptor agonist that acts centrally in the brain — not peripherally on genital tissue — to improve sexual desire, arousal, and responsiveness. It is the only FDA-approved peptide for a sexual function indication in women: Vyleesi received FDA approval in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a 1.75 mg subcutaneous autoinjector on-demand approximately 45 minutes before anticipated sexual activity. The pharmacology is fundamentally different from the PDE5 inhibitor class (sildenafil, tadalafil, vardenafil). PDE5 inhibitors work peripherally in the corpus cavernosum to maintain erectile blood flow once arousal has already begun. PT-141 works centrally in the hypothalamus, specifically on MC4R-expressing neurons, to create the upstream arousal signal itself. This means PT-141 can address sexual dysfunction that PDE5 inhibitors cannot — most notably desire and arousal disorders where the physiologic machinery is intact but the central arousal trigger is not firing. PT-141 evolved from earlier research on Melanotan-II, a broader-spectrum melanocortin agonist originally developed for photoprotective tanning indications. During Melanotan-II trials in the 1990s, an unexpected and consistent side effect emerged: spontaneous erections in male volunteers. Palatin Technologies (the developer) isolated the pharmacophore responsible, removed the pigmentation-driving MC1R activity to the extent possible, and produced bremelanotide — a more selective MC4R agonist with a cleaner side effect profile. Clinical trial data from the key RECONNECT Phase 3 program (Kingsberg et al., 2019) demonstrated statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) across two 24-week trials enrolling 1,247 premenopausal women with HSDD. Off-label use in men for erectile dysfunction and both sexes for general libido enhancement is widespread in the peptide research community, with typical subcutaneous doses ranging from 0.5 to 2 mg taken 30-60 minutes before anticipated activity. The most significant safety considerations are transient blood pressure elevation (typically +6-8 mmHg systolic, resolving within 8-12 hours), nausea (the single most commonly reported adverse event, affecting roughly 40% of users in clinical trials), and — with repeated use — dose-related hyperpigmentation caused by residual MC1R cross-reactivity.